unknown
Stage
1
Investors
About
Damona Pharmaceuticals is developing small-molecule precision neuromedicines to treat cognitive deficits associated with neurodegenerative and psychiatric disorders. Its lead candidate, DPX-101, is a positive allosteric modulator targeting the α5-GABA-A receptor for indications such as Alzheimer’s disease, depression, and schizophrenia.
Explore Damona Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.